LAZCLUZE™
(lazertinib)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
LAZCLUZE™ (lazertinib)
Medical Information
RYBREVANT - NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Last Updated: 10/28/2024
summary
- NCCN Guidelines®
for Non-Small Cell Lung Cancer (NSCLC) recommends amivantamab-vmjw (RYBREVANT) as1 : - First-line therapy option in combination with lazertinib for EGFR Exon 19 deletion or Exon 21 L858R mutation discovered prior to first-line systemic therapy (NCCN Category 1, other recommended). If EGFR mutation is discovered during first-line systemic therapy, amivantamab-vmjw is recommended in combination with lazertinib (NCCN Category 2A).
- Prophylactic anticoagulation is recommended for amivantamab-vmjw + lazertinib at the time of initiation to prevent venous thromboembolic events.
- Subsequent therapy option, if not previously given, in combination with carboplatin and pemetrexed for EGFR Exon 19 deletion or Exon 21 L858R mutation positive advanced, or metastatic nonsquamous disease after progression on osimertinib in patients with multiple systemic lesions who are symptomatic (NCCN Category 1, preferred).
- First-line therapy option in combination with carboplatin and pemetrexed for epidermal growth factor receptor (EGFR) Exon 20 insertion mutation positive advanced, or metastatic nonsquamous disease (NCCN Category 1, preferred).
- Subsequent therapy option as a single agent for EGFR Exon 20 insertion mutation positive advanced, or metastatic nonsquamous disease (NCCN Category 2A).
- First-line therapy option in combination with lazertinib for EGFR Exon 19 deletion or Exon 21 L858R mutation discovered prior to first-line systemic therapy (NCCN Category 1, other recommended). If EGFR mutation is discovered during first-line systemic therapy, amivantamab-vmjw is recommended in combination with lazertinib (NCCN Category 2A).
- National Comprehensive Cancer Network® (NCCN®) Categories of Evidence are defined as1:
- Category 1 is based upon high-level evidence, and there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
- Category 2A is based upon lower-level evidence, and there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
- NCCN Categories of Preference are defined as1:
- Preferred intervention is defined as interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
- Other recommended intervention is defined as other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
- Please refer to the NCCN Guidelines for NSCLC at www.nccn.org for current and complete recommendations for the use of amivantamab-vmjw in NSCLC1.
- Please refer to the full Prescribing Information for RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) for information on INDICATIONS & USAGE.2
, 3
- RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf
- LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf
References
| 1 | Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non- Small Cell Lung Cancer V9.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed September 12, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. |
| 2 | |
| 3 |